Review



cdk4 cdk6 inhibitor palbociclib  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    MedChemExpress cdk4 cdk6 inhibitor palbociclib
    Cdk4 Cdk6 Inhibitor Palbociclib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 194 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/Palbociclib/pm41862447-184-12-18
    Average 96 stars, based on 194 article reviews
    cdk4 cdk6 inhibitor palbociclib - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: GPER1 reduces skin inflammation by inhibiting keratinocyte proliferation
    Article Snippet: Larvae were treated from 24 hpf to 72 hpf with either the CDK4/CDK6 inhibitor Palbociclib (10 μM, #HY-50767, MCE) or with the GPER1 agonist G-1 (1, 0.5, 0.1 and 0.01 μM, #415919-74-3, Sigma-Aldrich) by bath immersion at 28 °C.

    Article Title: A Universal Scaling Law for Mitotic Spindles Driven by Chromosome Crowding
    Article Snippet: To obtain a predominantly population of 1:1 cells, 24 hours after seeding, cells were treated with CDK4/CDK6 inhibitor palbociclib (250 nM, HY-50767, MedChemExpress) .

    Article Title: GPER1 reduces skin inflammation by inhibiting keratinocyte proliferation.
    Article Snippet: Larvae were treated from 24 hpf to 72 hpf with either the CDK4/CDK6 inhibitor Palbociclib (10 μM, #HY-50767, MCE) or with the GPER1 agonist G-1 (1, 0.5, 0.1 and 0.01 μM, #415919-74-3, Sigma-Aldrich) by bath immersion at 28 oC.



    Similar Products

    cdk4 cdk6 inhibitor palbociclib  (MedChemExpress)
    96
    MedChemExpress cdk4 cdk6 inhibitor palbociclib
    Cdk4 Cdk6 Inhibitor Palbociclib, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/Palbociclib/pm41862447-184-12-18
    Average 96 stars, based on 1 article reviews
    cdk4 cdk6 inhibitor palbociclib - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    the cdk4 and cdk6 inhibitor palbociclib  (Millipore)
    90
    Millipore the cdk4 and cdk6 inhibitor palbociclib
    The Cdk4 And Cdk6 Inhibitor Palbociclib, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/palbociclib/pm35343570-213-22-27
    Average 90 stars, based on 1 article reviews
    the cdk4 and cdk6 inhibitor palbociclib - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdk4/cdk6 inhibitor palbociclib/ pd0332991 isethionate  (ApexBio)
    90
    ApexBio cdk4/cdk6 inhibitor palbociclib/ pd0332991 isethionate
    Cdk4/Cdk6 Inhibitor Palbociclib/ Pd0332991 Isethionate, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/palbociclib/pm35112712-71-8-13
    Average 90 stars, based on 1 article reviews
    cdk4/cdk6 inhibitor palbociclib/ pd0332991 isethionate - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdk4 and cdk6 inhibitors palbociclib pf-00080665  (Pfizer Inc)
    90
    Pfizer Inc cdk4 and cdk6 inhibitors palbociclib pf-00080665
    Antibodies used in this study.
    Cdk4 And Cdk6 Inhibitors Palbociclib Pf 00080665, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/palbociclib/pmc07403155-137-8-14
    Average 90 stars, based on 1 article reviews
    cdk4 and cdk6 inhibitors palbociclib pf-00080665 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdk4 and cdk6 inhibitor (palbociclib)  (Pfizer Inc)
    90
    Pfizer Inc cdk4 and cdk6 inhibitor (palbociclib)
    Clinical trials of combined therapy using cetuximab and immunotherapy
    Cdk4 And Cdk6 Inhibitor (Palbociclib), supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/palbociclib/pmc06635035-34-13-34
    Average 90 stars, based on 1 article reviews
    cdk4 and cdk6 inhibitor (palbociclib) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdk4/cdk6 inhibitor palbociclib pd0332991  (Selleck Chemicals)
    90
    Selleck Chemicals cdk4/cdk6 inhibitor palbociclib pd0332991
    Clinical trials of combined therapy using cetuximab and immunotherapy
    Cdk4/Cdk6 Inhibitor Palbociclib Pd0332991, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/palbociclib/pmc06459823-63-16-22
    Average 90 stars, based on 1 article reviews
    cdk4/cdk6 inhibitor palbociclib pd0332991 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdk4/cdk6 inhibitor palbociclib pd033299  (Selleck Chemicals)
    90
    Selleck Chemicals cdk4/cdk6 inhibitor palbociclib pd033299
    Clinical trials of combined therapy using cetuximab and immunotherapy
    Cdk4/Cdk6 Inhibitor Palbociclib Pd033299, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/palbociclib/pm27884981-239-3-10
    Average 90 stars, based on 1 article reviews
    cdk4/cdk6 inhibitor palbociclib pd033299 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdk4 and cdk6 inhibitor palbociclib  (Pfizer Inc)
    90
    Pfizer Inc cdk4 and cdk6 inhibitor palbociclib
    Clinical trials of combined therapy using cetuximab and immunotherapy
    Cdk4 And Cdk6 Inhibitor Palbociclib, supplied by Pfizer Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cdk4+cdk6+inhibitor+palbociclib/palbociclib/10__1146_slash_annurev___cancerbio___040716___075628-84-4-9
    Average 90 stars, based on 1 article reviews
    cdk4 and cdk6 inhibitor palbociclib - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Antibodies used in this study.

    Journal: British Journal of Cancer

    Article Title: CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms

    doi: 10.1038/s41416-020-0891-x

    Figure Lengend Snippet: Antibodies used in this study.

    Article Snippet: In this study, we analysed the potential of CDK4 and CDK6 inhibitors palbociclib (PF-00080665, Pfizer Ltd.) and ribociclib (GST0000015996, Novartis Pharma AG) as therapeutic options for cisplatin-resistant and -sensitive GCTs.

    Techniques: Western Blot, Immunohistochemistry, Immunofluorescence, Flow Cytometry

    Oligonucleotides used in this study.

    Journal: British Journal of Cancer

    Article Title: CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms

    doi: 10.1038/s41416-020-0891-x

    Figure Lengend Snippet: Oligonucleotides used in this study.

    Article Snippet: In this study, we analysed the potential of CDK4 and CDK6 inhibitors palbociclib (PF-00080665, Pfizer Ltd.) and ribociclib (GST0000015996, Novartis Pharma AG) as therapeutic options for cisplatin-resistant and -sensitive GCTs.

    Techniques:

    a Analysis of CDK4/6 expression in GCT tissues (type II GCTs, upper panel, Affymetrix microarray; type I GCTs, inlay in upper panel, qRT-PCR) and cell lines (middle panel: Illumina microarray; lower panel: RNA-seq data, RPKM = reads per kilobase million). As controls, normal testis tissue (NTT), the Sertoli cell line FS1 and fibroblasts (MPAF) were included. Standard deviation is given above bars. b Western blot analysis of CDK4, CDK6, RB1 and phospho-RB1 (pRB1) protein levels in GCT cell lines and controls (fibroblasts, Sertoli cells). HepG2 and HeLa cells served as positive controls for CDK4 and CDK6. GAPDH was used as housekeeper and for normalisation. c Immunohistochemical staining of CDK4 in GCT tissues (seminoma, EC, yolk-sac tumour and teratoma). Scale bar: 500 μm.

    Journal: British Journal of Cancer

    Article Title: CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms

    doi: 10.1038/s41416-020-0891-x

    Figure Lengend Snippet: a Analysis of CDK4/6 expression in GCT tissues (type II GCTs, upper panel, Affymetrix microarray; type I GCTs, inlay in upper panel, qRT-PCR) and cell lines (middle panel: Illumina microarray; lower panel: RNA-seq data, RPKM = reads per kilobase million). As controls, normal testis tissue (NTT), the Sertoli cell line FS1 and fibroblasts (MPAF) were included. Standard deviation is given above bars. b Western blot analysis of CDK4, CDK6, RB1 and phospho-RB1 (pRB1) protein levels in GCT cell lines and controls (fibroblasts, Sertoli cells). HepG2 and HeLa cells served as positive controls for CDK4 and CDK6. GAPDH was used as housekeeper and for normalisation. c Immunohistochemical staining of CDK4 in GCT tissues (seminoma, EC, yolk-sac tumour and teratoma). Scale bar: 500 μm.

    Article Snippet: In this study, we analysed the potential of CDK4 and CDK6 inhibitors palbociclib (PF-00080665, Pfizer Ltd.) and ribociclib (GST0000015996, Novartis Pharma AG) as therapeutic options for cisplatin-resistant and -sensitive GCTs.

    Techniques: Expressing, Microarray, Quantitative RT-PCR, RNA Sequencing, Standard Deviation, Western Blot, Immunohistochemical staining, Staining

    In GCTs, PaRi affects the cell cycle in three ways: a by inducing G1/G0 arrest via the CDK4–pRB1 axis, b by bypassing the G1/S checkpoint by upregulation of CDK3 and inducing an arrest at the end of the G2 phase or c by downregulating mitosis regulators leading to termination of mitosis. All described effects are not tolerated by GCT cells, eventually resulting in apoptosis.

    Journal: British Journal of Cancer

    Article Title: CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms

    doi: 10.1038/s41416-020-0891-x

    Figure Lengend Snippet: In GCTs, PaRi affects the cell cycle in three ways: a by inducing G1/G0 arrest via the CDK4–pRB1 axis, b by bypassing the G1/S checkpoint by upregulation of CDK3 and inducing an arrest at the end of the G2 phase or c by downregulating mitosis regulators leading to termination of mitosis. All described effects are not tolerated by GCT cells, eventually resulting in apoptosis.

    Article Snippet: In this study, we analysed the potential of CDK4 and CDK6 inhibitors palbociclib (PF-00080665, Pfizer Ltd.) and ribociclib (GST0000015996, Novartis Pharma AG) as therapeutic options for cisplatin-resistant and -sensitive GCTs.

    Techniques:

    Clinical trials of combined therapy using cetuximab and immunotherapy

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics

    doi: 10.1158/1078-0432.CCR-18-0871

    Figure Lengend Snippet: Clinical trials of combined therapy using cetuximab and immunotherapy

    Article Snippet: NCT03498378 , 1 , Incurable HNSCC , Cetuximab + avelumab + palbociclib , anti-PD-L1 Mab(avelumab) CDK4 and CDK6 inhibitor (palbociclib) , 24 (estimated) , MTD, ORR , UC San Diego Moores Cancer Center , Pfizer , Recruiting.

    Techniques: Clinical Proteomics, Recombinant, Biomarker Discovery